All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Heat-shock protein 90 (HSP90) is known to be a key member of the epichaperome complex that is involved in the maintenance of protein homeostasis during stressful and nonstress conditions, and known to be overexpressed in glioma tumors, conferring cancer cells survival and resistance to therapy. In this study, researchers at The University of Texas MD Anderson Cancer Center investigated the activity and toxicity profile of MPT-0B640, an HSP90 inhibitor, for treating gliomas and its ability to cross the blood-brain barrier (BBB) using glioma stem-like cell (GSC) lines.